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OVERVIEW
Interactions of cells with basement
membranes and the extracellular mat-
rices are crucial for various biologi-
cal processes, including the mainte-
nance of tissue integrity, embryoge-
nesis, wound healing, and the metas-
tasis of tumor cells. These process-
es involve cell adhesion and migra-
tion. Adhesive and migratory events
require certain biochemical entities,
formation of multiprotein complex
between these entities, and their func-
tional communication one another.
Cell adhesion is mediated through
cell adhesion receptors or transme-
mbrane glycoproteins binding to
extracellular matrix (ECM) or counter-
receptors on neighbor cells. Cell
adhesion receptor families include
cadherins, selectins, syndecans, and
the immunoglobulin superfamily of
cell adhesion molecules (IgCAMs).
In this review, integrin-mediated cel-
lular processes such as cell prolifer-
ation and apoptosis and their mole-
cular basis will be discussed based
on recent observations, although
other cell adhesion receptors can play
important roles or be involved in the
processes and recent outstanding
reviews are also available (1, 2).
1. INTEGRINS
Integrins comprise a large family of
transmembrane glycoprotein or integrins
are heterodimeric molecules composed
of an α and a β subunit, with long
extracellular domains binding to ECM
and short cytoplasmic domains associ-
ating with the actin cytoskeleton and
affiliated proteins (3). The integrin
receptor family in mammals includes
at least 18 distinct α subunits and 8 or
more β subunits which can potentially
generate 24 distinct αβ heterodimeric
receptors (4). Major ECMs include
fibronectin, laminin, and collagen. By
communicating with both ECM and
intracellular proteins simultaneously,
cells are able to respond to extracellu-
lar cues through actions of intracellu-
lar signaling components as well as to
transduce intracellular signal toward
outside of a cell. Further, evidences are
being accumulated over the past sev-
eral years to show that integrins are
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important component not only for the
structure and architecture of tissues but
also for signal transduction leading to
regulation in many biological func-
tions in a cell.  The signaling through
integrin receptors can be classified to
two categories; direct signaling by
engagement itself of cells via integrins
on the surface of a cell and co-signal-
ing upon cooperation with growth fac-
tor stimulation of receptor tyrosine
kinases (RTKs) of an anchored cell
(Figure 1). In next sections, both sig-
naling will be discussed one by one.
2. INTEGRIN SIGNALING
Cell adhesion to ECMs can direct-
ly activate diverse intracellular sig-
naling molecules, including Focal
Adhesion Kinase (FAK), Erk and c-
Jun kinase (JNKs) MAP kinases, and
small Rho GTPase family members
including RhoA, Rac1, and CDC42.
These important molecules regulate
cell adhesion, spreading, prolifera-
tion, survival (or apoptosis), and mor-
phological changes of diverse cell
types including epithelial cells,
endothelial cells, fibroblasts, other
mesenchymal cell types, and even
immune cells.
2.1. Direct signaling for FAK acti-
vation.
Dr. Juliano group, this author’s Ph.D.
advisor, first revealed the enhanced
intracellular tyrosine phosphorylation
upon integrin-mediated cell adhesion,
indicating that cell adhesion trigger
signal transduction involving phospho-
tyrosine proteins (5). Soon after other
studies revealed that among the phos-
photyrosine molecules non-receptor
tyrosine kinase known as FAK was
activated by cell adhesion (6). When a
cell adheres to ECM or is seeded onto
a dish precoated with a specific ECM
like fibronectin, it adheres to ECM
through specific sites within the cell
where the integrin-rich adhesion stru-
ctures known as focal adhesions or
Figure 1. Direct signaling by integrins (A) and co-signaling by collaboration
between integrins and receptor tyrosine kinases (RTKs) (B). Upon integrin
binding to extracellular matrix proteins (ECMs), integrins are clustered, acti-
vated, and associate with the actin cytoskeleton, leading to assembly or
recruitment of downstream signaling molecules to activate intracellular kinas-
es (A). Integrins also collaborate with signaling molecules responding to growth
factor-mediated RTKs activation, leading to diverse biological processes (B).
Collaboration with oth-er signal pathway, for example G-protein coupled recep-
tors (GPCRs) signal pathway, is also available (76). 
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focal contacts (7). In a focal adhesion,
integrins are linked to actin filaments
by virtue of a number of signaling and
structural molecules including FAK, c-
Src, PI-3-Kinase, RhoGAP, paxillin,
talin, P130Cas, integrin-linked kinase
(ILK), and phosphorylated caveolin-1
(8). The protein complex resulting
from these interactions can serve as a
structural and functional link between
integrins and the actin-containing
cytoskeleton.
FAK has a unique structure as a mem-
ber of the family of protein tyrosine
kinases. FAK shares little sequence
homology with other tyrosine kinases
outside its kinase domain, is not a
transmembrane protein, contains no
lipid modification or acylation sites,
and lacks SH2 and SH3 domains. It
contains three domains; a central
kinase domain, an N-terminal domain
binding to β1 integrin cytoplasmic
domain peptides (9), and a COOH-ter-
minal domain with two proline-rich
sequence motifs and a region required
for focal adhesion targeting called the
“FAT” sequence (9). FAK is phos-
phorylated in many tyrosine residues
and activated upon integrin-mediated
adhesion, and dephosphorylated when
cells are detached (10). Although how
these happen is not clearly revealed
yet, the consequent signaling follow-
ing activation of FAK have been
actively studied by many groups
worldwide.
FAK is autophosphorylated in
response to integrin activation, pre-
dominantly on Tyr397, which con-
forms to the consensus binding for
SH2 domains for c-Src (11), p85 reg-
ulatory subunit of PI-3-Kinase and
Grb7 (12) (Figure 2). Src interaction
with FAK leads to phosphorylation
of FAK at several sites including
Tyr407, Tyr576, Tyr577, Tyr861, and
Tyr925, which then results in the adap-
tor protein Grb2 binding to FAK at
residue Tyr925 (13). Grb2 binding to
FAK has been proposed as a possi-
ble link between FAK tyrosine phos-
phorylation and the integrin-mediat-
ed activation of MAPK (14). It has
become apparent that FAK, Src,
P130Cas and paxillin form a signaling
complex at cell adhesion sites, whose
assembly is normally initiated by
autophosphorylation of FAK (15).
Cell adhesion and spreading has
been indexed by FAK activation in
numerous studies (16). FAK also
appear to control cell spreading and
migration (17). FAK is also an impor-
tant mediator of cell survival in some
models (18). Previous studies indi-
cated that a constitutively active form
of FAK can facilitate anchorage-inde-
pendent growth and protection from
Figure 2. Structural features and signaling of FAK. FAK consists of a cen-
tral kinase domain flanked by N- and C-terminal sequences. The N-terminal
sequence contains a FERM domain and a praline-rich (PR) SH3 binding motif.
The C-terminal sequence harbors the focal adhesion targetomg (FAT) domain
with two PR motifs. Upon cell adhesion, Y397 of FAKis autophosphorylated
by its own kinase activity and then phosphorylated pY397 can recruit diverse
molecules, of which c-Src can in turn phosphorylate Y925, which recruit again
directly or indirectly (via Shc) Grb2, leading to signaling to Ras/Raf-1/MRK/Erk
cascade. Other down stream signaling pathways and protein interactions are
also indicated. 
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suspension-mediated apoptosis (anoikis)
in MDCK epithelial cells (18). Inac-
tivation of FAK by microinjection of
a peptide representing the FAK-bind-
ing site of the beta 1 tail coupled to
a carrier protein into fibroblasts caus-
ed rapid apoptosis (19). The mecha-
nisms by which FAK protects cells
from apoptosis (and anoikis) are not
clear, but FAK association with Src
and/or PI-3-K at Tyr397 is predicted
to be necessary (18). Recently the
FAK-P130Cas complex was shown to
activate JNK via a Ras/Rac1/Pak1-
/MAPK kinase 4 (MKK4) pathway,
resulting in survival of fibroblasts on
fibronectin when serum was with-
drawn (20). In addition, a recent
report implicated phospholipase A2
(PLA2), PKC, and p53 in FAK-medi-
ated cell survival (21). However,
FAK is not always involved in cell
survival. In a study where α5 inte-
grin subunit mediated cell survival
of CHO transfectants stressed by
serum deprivation, FAK phosphory-
lation was not correlated with the
anti-apoptotic effects (22).
2.2 Direct signaling for activation
of MAP kinase cascade.
In addition to FAK, MAP kinases
including of Erk1/2 and c-Jun kinase
(JNKs), and p38 MAPK are well
known to be activated by integrin-
mediated cell adhesion. Activation of
MAPK (or Erk1/2) pathway by cell
adhesion provides a common route
leading to transcriptional regulation
of certain genes. The products of
these genes are critical for cell grow-
th and differentiation (23). However,
the intriguing and somewhat contro-
versial aspects of their activation
mechanisms have not yet clearly
explained.
The exact mechanism of integrin-
mediated activation of Erk1/2 is not
yet known.  However, there are sev-
eral plausible mechanisms for the
integrin-mediated activation of Erk1-
/2. One mechanism involves Src
mediated phosphorylation of FAK
Tyr925, as explained above. FAK
autophosphorylates Tyr397, creating a
docking site for the Src homology 2
(SH2) domain of Src or Fyn (24).
Src phosphorylates FAK at Tyr925,
creating a binding site for the sig-
naling complex including adaptor
protein Grb2 and Ras GTP-exchange
factor mSOS (24). These interactions
between signaling or structural mol-
ecules link FAK to signaling path-
ways that modify the organization of
cytoskeleton and Erk1/2 cascade (25).
It has also been proposed that Shc
may be responsible for the initial high
level activation of Erk1/2 through a
complex formation with Shc/Fyn/Cav-
1 upon cell adhesion, and FAK,
which is activated more slowly, may
sustain the Erk1/2 activation (26).
The pathway involving Shc is quite
distinct from the other proposed path-
ways involving FAK, which involve
b subunit cytoplasmic domains. Cer-
tain a integrin subunits bind to the
membrane protein caveolin-1, throu-
gh their external and transmembrane
domains (26).  Upon interaction with
Fyn, Shc is phosphorylated at Tyr317
and recruits Grb2, leading to Ras/
Erk1/2 cascade activation. Recently
it was reported that the Shc and FAK
pathways are activated independent-
ly and function in a parallel fashion,
and that FAK might enhance and pro-
long integrin-mediated activation of
Erk1/2 through p130Cas, CrkII, and
Rap1 in cells expressing B-Raf (27).
This suggests that, depending on the
Raf isoforms (Raf-1 vs. B-Raf), inte-
grin signaling to Erk1/2 is either
through Shc (when Raf-1 is high) or
FAK (when B-Raf is high).  This
suggestion is consistent with anoth-
er observation that the C3G-CrkII
complex (upst-ream of B-Raf) plays
a negative role in anchorage-depen-
dent regulation of Erk1/2 activation,
but hat this was reversed by over-
expression of B-Raf (28). Therefore,
these indicate that the ratio of Raf-
1 vs B-Raf depending on cell con-
texts determine the precise details of
integrin signaling to Erk1/2. Anoth-
er possible mechanism for integrin-
stimulated Erk1/2 activation involves
PI-3-K, which may activate Raf-1
through activation of PKC isoforms
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(29,30). These studies do not indi-
cate a direct role for FAK in the acti-
vation of Erk1/2. In one study, over-
expression of a constitutively acti-
vated form of FAK failed to activate
Erk1/2, and in a separate study over-
expression of a dominant-negative
form of FAK blocked FAK activa-
tion, but had no effect on Erk1/2
activation (31).The models described
above include the activation of Ras
in the integrin-mediated activation of
Erk-1/2, supported by studies using
a Ras dominant-negative (Ras N17)
to block the adhesion activation of
Erk1/2 (32). Other studies, however,
indicate a Ras-independent activation
of Erk1/2. When the N-terminal
domain of Raf was used as a spe-
cific dominant-negative inhibitor of
Ras signaling, the activation of
Erk1/2 was not affected (33). Fur-
ther, a recent study shows that Raf
can be activated via integrin-medi-
ated adhesion when it contains muta-
tions in the Ras-binding domain of
Raf and thereby cannot bind to Ras,
also supporting a Ras-independent
activation of Erk1/2 (34). In addition
to Erk1/2, JNKs and p38 MAPK are
also known to be activated by inte-
grin signaling. The integrin-mediated
JNKs activation is dependent on FAK
and involved in cell survival (20),
cell cycle progression (35), or cell
spreading (36). On the other hand,
p38 is activated by integrins for reg-
ulation of collagen gene expression
(37), cell motility (38), or function-
al expression of integrin αv subunit
and urokinase plasminogen activator
(uPA) (39). The physiological sig-
nificance of integrin-mediated acti-
vation of MAP kinases is not clear,
since the activity of Erk1/2 mediat-
ed by cell adhesion alone is not suf-
ficient for the cell cycle traverse. That
is, additional signals provided by
growth factors though integrin co-
signaling with receptor tyrosine
kinases (RTKs) are still needed.  In
addition, morphological rearrange-
ment modulated by integrin-mediat-
ed activation of small GTPase fam-
ily members and/or actin cytoskele-
tal integrity is also shown to be




Beyond the trend that many research-
es have indicated a link between inte-
grin-ECM interaction and thereby sig-
naling and activation of Ras/Raf-
1/MEK/MAPK(Erk) pathway, a path-
way downstream of the prototype
member of the Ras superfamily of
small GTPase, recently much research
has also indicated that integrin-medi-
ated signaling also activates other
members of the Ras superfamily,
notably the Rho family members of
small GTPase including RhoA, Rac1,
and CDC42 (Figure 3). It is well
known that integrin-mediated activa-
tion of RhoA, Rac1, or CDC42
rearranges the actin cytoskeletal net-
work, leading to morphological features
of stress fiber formation/focal adhesion
turnover, lamellipodia, or filopodia for-
mation, respectively (43). By virtue of
that these small GTPases are important
to regulate actin cytoskeleton, they influ-
ence diverse key cellular processes (44).
The mechanisms how the GTPases reg-
ulate actin cytoskeleton are being active-
ly studied and revealed some down
stream effectors.  Both RhoA-stimu-
lated kinase ROCK and Rac-1 stimu-
lated kinase p21activated kinase
(PAK1) can phosphorylate and there-
by activate LIM kinase, which in turn
phosphorylates and inactivates cofilin
(an actin depolymerizing protein), thus
leading to promotion of actin filament
assembly (45). On the other hand, acti-
vation of Rac1 and CDC42 can be
linked to actin polymerization, though
mediation by WASP, WAVE adaptor
proteins, and the Arp2/3 complex in
forming actin filaments (45,46).
During branching of actin filaments
via the Arp2/3 complex, c-Src-medi-
ated activation of cortactin is required
for the bridge of the Arp2/3 complex
to actin filaments (47). It is now clear
that activation or deactivation of RhoA
GTPase family members when cells
adhere to ECMs is a key event for
localized control of actin filament
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assembly, contractility, and cell motil-
ity. In addition to their roles in actin
filament reorganization, RhoA GTP-
ases have been shown to be important
for cell cycle progression (25).
Interestingly, activated GTPases are
shown to regulate cell cycle progres-
sion, by modulating the levels of the
G1 phase cyclin, cyclinD, transcrip-
tionally or translationally, or the induc-
tion timing of the cyclin D during the
G1 phase (25, 40, 41, 48). It was shown
that Rac1 activation leads to an
enhanced transcription of cyclin D
(49), via NF-κB transcription activity
in fibroblast cells (50). Rac1 is also
shown to regulate cyclin D level at the
translational level of endothelial cells
following activation of Shc and FAK,
through mediation of SOS and PI-3-K
(41). In addition, it was found that Rho
is involved in the accumulation of
cyclin D protein by fibronectin and the
same time reduction of p21Cip/Waf was
observed (51). Interestingly, Welsh et
al. (48) reported that Rho inhibited an
alternative Rac/Cdc42-dependent path-
way, which resulted in a strikingly
early G1-phase expression of cyclin
D1, and that cyclin D1 was induced in
mid-G1 phase because a Rho switch
couples its expression to sustained
ERK activity rather than Rac-1 and
Cdc42, allowing a RhoA switch cru-
cial for maintaining the correct timing
of cyclin D1 expression in G1 phase.
Being consistent with the implication
by the small GTPase studies to cell
proliferation, evidences were reported
that intact actin cytoskeletal network
integrity is also critical for G1/S tran-
sition; demolishing of the network by
a pharmacological reagent inhibited
Figure 3. Integrin signaling to regulate the cytoskeleton through Rho GTPas-
es. Although the precise mechanism to regulate Rho GTPases upon cell adhe-
sion, downstream effectors of Rho GTPases and their contribution to cellular
morphology are shown. In contrast to inactivation of RhoA by p190RhoGAP
in earlier (fast) times upon cell spreading, integrin-mediated RhoA activation
result in Rho kinase (ROCK) to activate myosin through direct phosphoryla-
tion of the light chain and by inhibition of myosin light chain phosphatase
(MLCP), leading to stress formation. In addition, RhoA interacts with mDia1
to regulate actin filament formation. Meanwhile, Activation of PAK1 by Rac1
leads to activation of LIMK and consequently inhibition of its downstream tar-
get, the actin depolymerizing protein cofilin, thereby promoting actin filament
polymerization. CDC42 binds to WASP to activate the Arp2/3 to trigger filopo-
dia formation, and Rac1 also activate WAVE via interaction with IRSp53, lead-
ing to activation of Arp2/3 to cause lamellipodia formation (images from (43).
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G1/S transition (42). Interestingly,
Rac1 activation in hepatocarcinoma
cells resulted in preferential G1/S tran-
sition, depending on ECM on which
cells were newly replated, indicating,
although cyclin D levels were similar
one another in an ECM-independent
manner but cyclin A levels were dif-
ferentially regulated (78), indicating
another step of cell proliferation pre-
sumably regulated by small GTPases.
In the cases that Rho GTPaes are
involved in cell cycle progression
through regulation of cyclin levels, not
only integrin-mediated activation of
GTPases but also mitogenic stimula-
tion of signal activation (e.g., Erk1/2)
will be required, because integrin-
mediated activation of signaling alone
is not sufficient for cell cycle traverse.
Therefore, in the observations expl-
ained above for the roles of the
GTPases in cell cycle regulation would
be performed in the conditions where






By virtues of collaborative signaling
by integrins with other cell surface
receptors such as receptor tyrosine
kinases (RTKs) or G-protein coupled
receptors (GPCRs), integrin-mediated
cell anchorage has been observed to
have profound effects, in terms of
amplitude, duration, and/or spatial
aspects on signaling processes. There
are several known intracellular signal-
ing molecules that are activated syn-
ergistically by both integrins and
growth factor receptors. They include
the Ras/Raf-1/-MEK/Erk1/2 pathway,
Rho family GTPase, PI-3-K, ribosomal
S6 kinase (RSK), Jun amino-terminal
kinase (JNK), FAK and paxillin, and
p130cas (reviewed in (52,53). Since the
G1 to S phase transition or S phase
entry has been shown to be regulated
by mitogenic reagents, cell adhesion,
and intact cytoskeletal network integri-
ty (as explained earlier), this collabo-
ration allows cells to integrate posi-
tional information as to cell-cell or cell-
ECM contacts, with information of ren-
dering cell growth. 
3.1. Integrin co-signaling with RTKs. 
Over the last few years, there have
been profound evidences that inte-
grin-mediated signaling can influence
the RTK-initiated signaling.  The col-
laboration has been reported that inte-
grin engagement and the presence of
growth factors are required to pro-
mote efficient activation (and auto-
phosphorylation) of RTK, such as
EGF, PDGF, and FGF receptors
(1,52). On the other hand, there were
at least two examples that integrin
mediated regulation of RTK activa-
tion occurs in the absence of growth
factors one with PDGF-β receptor (54)
and the other with EGFR (55). In
these systems, enhanced RTK phos-
phorylation was correlated with cell
proliferation and/or survival. The first
demonstration of a growthfactor-
dependent physical association bet
ween an RTK and an integrin mol-
ecule involved PDGFRβ and αvβ3 in
human foreskin fibroblasts (56). This
study showed that fibroblasts on vit-
ronectin, a ligand for the αvβ3 inte-
grin, display enhanced growth and
MAPK activation in response to
PDGFRβ compared to cells cultured
on non-αvβ3 ligands.  Further, an
association between a highly phos-
phorylated fraction of the PDGFRβ
and αvβ3 integrin was promoted by
PDGF, indicating a direct effect of
ECM on the RTK signaling pathway.
In contrast, normal human bronchial
epithelial cells on collagen type I
showed enhanced retinoid-induced
differentiation, by restriction of the
amount of EGFR-dependent Erk1/2
activation; integration between the
ECM- and EGFR-derived signaling
pathways lies downstream of EGFR
autophosphorylation and at, or upstre-
am of, Raf-1 activation (57). Anoth-
er recent study has shown that inte-
grins can induce EGFR tyrosine
phosphorylation in the absence of
EGFR ligands, leading to Shc tyro-
sine phosphorylation and Erk1/2 acti-
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vation (55). In this study, physical
interaction between β1 integrin sub-
unit and EGFR has been shown.  Fur-
ther, it was concluded that integrin-
mediated tyrosine phosphorylation of
the EGFR requires activation of
receptor tyrosine kinase activity,
based on an EGFR kinase inhibitor
study.  Importantly, Moro et al. (55)
showed that adhesion-induced EGFR
activation does not induce cell pro-
liferation, but was shown to protect
EGFR-transfected NIH3T3 cells from
serum deprivation-mediated apoptosis.
Therefore, it is possible that the inten-
sity and duration of EGFR transac-
tivation and subsequent MAPK
(Erk1/2) (or other downstream effec-
tors) activation represent a decision
point between cell proliferation and
alternative pathways such as cell sur-
vival.
3.2. Regulation of Ras/Raf-
1/MEK/ERks cascade by integrin
co-signaling with RTKs. 
Integrin regulation of RTK-emanated
signaling to the Ras/Raf-1/MEK/Erks
cascade has been interesting due to the
dependency of cell cycle progression
on the presence of growth factors and
at the same time cell adhesion.  The
levels where integrins can modulate
RTKs/Ras/Raf-1/MEK/Erks have been
shown the RTK (55), activation of
Raf-1 (58), activation of MEK (59),
and nuclear translocation of activated
Erk1/2 (60) (Figure 1). As for the RTK
level regulation by integrins, it appears
obvious that formation of direct or
indirect complexes between the RTKs
and the integrins could lead to
enhanced opportunities for RTK
dimerization and cross-posphorylation.
This author have reported that integrin
α5β1, but not α2β1, expression in nor-
mal rat intestinal epithelial cells allows
preferential survival of cells from
serum deprivation through differential
activation of PKB/Akt (61), and that
this effect was possible via the differ-
ential activation of EGFR signaling to
PI-3-K/PKB survival pathway, but
equal activation to Erk1/2, through dif-
ferential formation of signaling com-
plexes including activated EGFR,
ErbB3, p85 regulatory domain of PI3-
K, and integrin α5 subunit (62).
Presumably indirect interaction bet-
ween EGFR or PDGFR and integrins
via a complex including FAK (N-ter-
minus binding to RTKs), paxillin
(binding to α4 integrin subunit), and
talin (binding to integrin β1 subunit)
has also been reported leading to acti-
vation of Erk1/2 (63). In cases that
integrin signaling regulates the cou-
pling between upstream and down-
stream components in the Ras/Raf-
1/MEK/Erks cascade, the regulation
steps were diverse, such as from Ras
to Raf-1 (58), from Raf-1 to MEK
(59), upstream of Raf-1 (64), associa-
tion of RasGAP to RTK (i.e., upstream
of Ras) (65). These differences may be
due to differences in cell types and sig-
naling contexts. These anchorage-
dependent regulations of Ras/Raf-
1/MEK/Erks cascade appear clearly
dependent on actin-cytoskeleton, since
disruption of the focal adhesions and
stress fibers by cytochalasin D treat-
ment did not affect Erk activation by
growth factors (66). However, in the
same study CDC42-dependent promo-
tion of cortical actin assembly was
shown important for the Erk activa-
tion, indicating that integrin-mediated
cell adhesion and subsequent actin
cytoskeleton organization can regulate
upstream to downstream coupling of
Ras/Raf-1/MEK/Erks intracellular sig-
naling cascade.  Another point of inte-
grin-mediated regulation for RTK sig-
naling is interesting. Recently it was
reported that cell adhesion can regu-
late trafficking of activated Erk1/2
from cytosol to nucleus (60). Thus, in
suspension cells, or in cells treated
with cytochalasin D, the normal nucle-
us translocation of activated Erk is
impossible because of disrupted
cytoskeleton presumably acting as a
traffic guide.  Therefore, even enforced
activation of Erk by using of active
Raf-1 or MEK could not allow translo-
cation of active Erk1/.2 to nucleus and
phosphorylation of its target, Elk-1
(60).
3.3. Integrin co-signaling with
… 분자세포생물학뉴스34
TGF-β pathway
Integrin engagement has been
shown to influence expression of
cytokines and their receptors, espe-
cially TGF-β1 and its receptors.
Transforming growth factor- (TGF-)
β1 is a multifunctional cytokine to
inhibit epithelial cell growth.  It trig-
gers intracellular signal transduction
involving SMAD proteins to regulate
numerous developmental and home-
ostatic processes via regulations in
genes induction (67). Recently, TGF-
β1-mediated, but SMAD-independent
signaling pathways have also been
evidenced in many model systems
(68). For example, TGF-β1-mediat-
ed activation of p38 MAPK and
JNKs resulted in increases in ECMs
such as collagen and fibronectin lev-
els, respectively (69,70). Similarly, in
diverse model systems, expression
profiles of integrins are susceptible
to regulation by TGF-β1 (71), and
integrin-mediated signaling also reg-
ulates the expression level of TGF-
β1 (72). Overexpression of integrin
α5β1 leads to upregulation of TGF-
β1 receptor type II and growth inhi-
bition (73), and conversely TGF-β1
treatment of NRK fibroblasts leads
to upregulation of integrin α5β1
expression and a loss of anchorage-
dependent growth (74). Similar to
growth factor receptors or GPCRs,
TGF-β1 receptor mediated signal
pathway is also cooperative with inte-
grin signaling.  Recently, it was
reported that TGF-β1 treatment to
mammary epithelial cells resulted in
epithelial-mesenchymal transdifferen-
tiation (EMT) and this effects were
dependent on both functional integrin
β1 and activity of p38 MAPK (75).
In addition, this author and col-
leagues found that TGF-β1 treatment
to epithelial cells results in c-Src
activity dependent cell adhesion and
Erk activity (77), and cause mor-
phological changes leading to acti-
vation of c-Src and small GTPases
such as Rac1 and CDC42, resulting
in preferential S-phase entry in a
GTPase activity-dependent manner
when cells were seeded on fibron-
ectin (78).
4. CONCLUDING REMARKS.
The interaction of cells via cell
adhesion receptors, integrins, to
extracellular matrix proteins has pro-
found effects on diverse cellular
processes. These roles of integrins
seem to be driven by the not only
structural bridge between extracellu-
lar matrix proteins and intracellular
actin cytoskeleton, but also signal
transduction by integrin alone and/or
collaboration with other receptors
such as RTKs. During these roles,
cytoskeleton and other signaling mol-
ecules such as small GTPases func-
tion very closely and most impor-
tantly. Since the cellular processes
regulated by integrin and their sig-
naling are involved diversely in cel-
lular function, studies on integrin and
their signaling may have critical
impacts on understanding or devel-
opment of reagent to cure human dis-
eases such as cancers.  So, as expect-
ed in other scientifically (more direct-
ly, in terms of cell signaling) devel-
oped countries, coming years can be
fruitful for our domestic researches.
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